Methylphenidate exerts neuroprotective effects through the AMPK signaling pathway

Area of Science:

• Neuroscience
• Pharmacology
• Cell Biology

Background:

• Cerebral ischemia is a leading cause of permanent adult disability globally.
• Understanding reparative mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the neuroprotective effects of methylphenidate (MPH) in cerebral ischemia-reperfusion injury.
• To elucidate the underlying molecular mechanisms, particularly the role of the AMPK pathway.

Main Methods:

• Established in vitro oxygen-glucose deprivation/reperfusion (OGD/R) and in vivo cerebral ischemia-reperfusion models in Sprague-Dawley rats.
• Assessed cell viability (MTT assay), apoptosis (Annexin V/PI staining), protein expression (Western blot), cerebral infarction volume (TTC staining), and DNA damage (TUNEL assay).
• Investigated the involvement of the AMPK/ACC pathway and the effect of an AMPK inhibitor.

Main Results:

• MPH treatment significantly reduced OGD/R-induced cell damage, increasing cell viability and decreasing apoptosis.
• MPH administration upregulated p-AMPK and p-ACC protein expression in OGD/R models.
• Inhibition of AMPK largely abolished MPH's neuroprotective effects, indicating pathway involvement.
• MPH treatment ameliorated cerebral ischemia-reperfusion injury and reduced apoptosis in brain tissues.

Conclusions:

• Methylphenidate (MPH) demonstrates protective effects against oxidative stress and brain damage in cerebral ischemia-reperfusion models.
• These neuroprotective properties are, at least partly, mediated by the activation of the AMPK pathway.
• MPH emerges as a potential therapeutic agent for mitigating cerebral ischemia-reperfusion injury.